AI Verdict
MBNKO has stronger fundamentals based on our AI analysis.
MBRX vs MBNKO Fundamental Comparison
| Metric | MBRX | MBNKO |
|---|---|---|
| Revenue | $0.0 | $315.3M |
| Net Income | $-33.6M | $43.0M |
| Net Margin | N/A | 13.7% |
| ROE | -223.6% | 10.5% |
| ROA | -151.7% | 1.5% |
| Current Ratio | 1.41x | N/A |
| Debt/Equity | 0.00x | 0.53x |
| EPS | N/A | $1.78 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MBRX vs MBNKO: Frequently Asked Questions
Is MBRX or MBNKO a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MBNKO has stronger fundamentals. MBRX is rated STRONG SELL (95% confidence) while MBNKO is rated HOLD (62% confidence). This is not investment advice.
How does MBRX compare to MBNKO fundamentally?
Moleculin Biotech, Inc. has ROE of -223.6% vs MEDALLION FINANCIAL CORP's 10.5%. Net margins are N/A vs 13.7% respectively.
Which stock pays higher dividends, MBRX or MBNKO?
MBRX has a dividend yield of N/A or no dividend while MBNKO has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MBRX or MBNKO for long term?
For long-term investing, consider that MBRX has STRONG SELL rating with 95% confidence, while MBNKO has HOLD rating with 62% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MBRX vs MBNKO?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MBRX vs MBNKO, the AI consensus favors MBNKO based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.